334 related articles for article (PubMed ID: 22453200)
1. Oral micronized progesterone for vasomotor symptoms--a placebo-controlled randomized trial in healthy postmenopausal women.
Hitchcock CL; Prior JC
Menopause; 2012 Aug; 19(8):886-93. PubMed ID: 22453200
[TBL] [Abstract][Full Text] [Related]
2. Hot flushes and night sweats differ in associations with cardiovascular markers in healthy early postmenopausal women.
Hitchcock CL; Elliott TG; Norman EG; Stajic V; Teede H; Prior JC
Menopause; 2012 Nov; 19(11):1208-14. PubMed ID: 22781788
[TBL] [Abstract][Full Text] [Related]
3. Progesterone for hot flush and night sweat treatment--effectiveness for severe vasomotor symptoms and lack of withdrawal rebound.
Prior JC; Hitchcock CL
Gynecol Endocrinol; 2012 Oct; 28 Suppl 2():7-11. PubMed ID: 22849758
[TBL] [Abstract][Full Text] [Related]
4. Progesterone therapy increases free thyroxine levels--data from a randomized placebo-controlled 12-week hot flush trial.
Sathi P; Kalyan S; Hitchcock CL; Pudek M; Prior JC
Clin Endocrinol (Oxf); 2013 Aug; 79(2):282-7. PubMed ID: 23252963
[TBL] [Abstract][Full Text] [Related]
5. The effects of micronutrient supplementation on vasomotor symptoms in postmenopausal women.
Andrikoula M; Baker D; Nesic J; Liao LM; Duka T; Prelevic GM
Climacteric; 2011 Oct; 14(5):544-50. PubMed ID: 21413865
[TBL] [Abstract][Full Text] [Related]
6. A double-blind placebo-controlled study to evaluate the effect of progestelle progesterone cream on postmenopausal women.
Benster B; Carey A; Wadsworth F; Vashisht A; Domoney C; Studd J
Menopause Int; 2009 Jun; 15(2):63-9. PubMed ID: 19465671
[TBL] [Abstract][Full Text] [Related]
7. Progesterone for treatment of symptomatic menopausal women.
Prior JC
Climacteric; 2018 Aug; 21(4):358-365. PubMed ID: 29962247
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation the efficacy and safety of estradiol and drospirenone tablets in the treatment of menopausal symptoms among postmenopausal Chinese healthy women:a randomized, multi-center, double-blind, placebo-controlled clinical study].
Zhou YZ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Lin SQ
Zhonghua Fu Chan Ke Za Zhi; 2011 May; 46(5):345-9. PubMed ID: 21733370
[TBL] [Abstract][Full Text] [Related]
9. Oral micronized progesterone for perimenopausal night sweats and hot flushes a Phase III Canada-wide randomized placebo-controlled 4 month trial.
Prior JC; Cameron A; Fung M; Hitchcock CL; Janssen P; Lee T; Singer J
Sci Rep; 2023 Jun; 13(1):9082. PubMed ID: 37277418
[TBL] [Abstract][Full Text] [Related]
10. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial.
Pinkerton JV; Constantine G; Hwang E; Cheng RF;
Menopause; 2013 Jan; 20(1):28-37. PubMed ID: 23010882
[TBL] [Abstract][Full Text] [Related]
11. Estradiol 1 mg and drospirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women.
Lin SQ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Zhou YZ; Wang ML; Zhu J; Chen SR; Su H; Yang CS; Wang SH; Zhang YZ; Dong XJ
Climacteric; 2011 Aug; 14(4):472-81. PubMed ID: 21469973
[TBL] [Abstract][Full Text] [Related]
12. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.
Bachmann GA; Schaefers M; Uddin A; Utian WH
Obstet Gynecol; 2007 Oct; 110(4):771-9. PubMed ID: 17906008
[TBL] [Abstract][Full Text] [Related]
13. Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.
Simon JA; Kaunitz AM; Kroll R; Graham S; Bernick B; Mirkin S
Menopause; 2019 May; 26(5):506-512. PubMed ID: 30489424
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.
Speroff L; Gass M; Constantine G; Olivier S;
Obstet Gynecol; 2008 Jan; 111(1):77-87. PubMed ID: 18165395
[TBL] [Abstract][Full Text] [Related]
15. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.
Aldrighi JM; Quail DC; Levy-Frebault J; Aguas F; Kosian K; Garrido L; Bosio-Le Goux B; Saráchaga M; Graebe A; Niño AJ; Nickelsen T
Am J Obstet Gynecol; 2004 Dec; 191(6):1979-88. PubMed ID: 15592280
[TBL] [Abstract][Full Text] [Related]
16. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms.
Gordon S; Walsh BW; Ciaccia AV; Siddhanti S; Rosen AS; Plouffe L
Obstet Gynecol; 2004 Feb; 103(2):267-73. PubMed ID: 14754694
[TBL] [Abstract][Full Text] [Related]
17. Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial.
Pinkerton JV; Archer DF; Guico-Pabia CJ; Hwang E; Cheng RF
Menopause; 2013 Jan; 20(1):38-46. PubMed ID: 23266839
[TBL] [Abstract][Full Text] [Related]
18. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 1-year randomized, double-blind, placebo-controlled study.
D'Anna R; Cannata ML; Atteritano M; Cancellieri F; Corrado F; Baviera G; Triolo O; Antico F; Gaudio A; Frisina N; Bitto A; Polito F; Minutoli L; Altavilla D; Marini H; Squadrito F
Menopause; 2007; 14(4):648-55. PubMed ID: 17251874
[TBL] [Abstract][Full Text] [Related]
19. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms.
Simon JA;
Menopause; 2006; 13(2):222-31. PubMed ID: 16645536
[TBL] [Abstract][Full Text] [Related]
20. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 2-year randomized, double-blind, placebo-controlled study.
D'Anna R; Cannata ML; Marini H; Atteritano M; Cancellieri F; Corrado F; Triolo O; Rizzo P; Russo S; Gaudio A; Frisina N; Bitto A; Polito F; Minutoli L; Altavilla D; Adamo EB; Squadrito F
Menopause; 2009; 16(2):301-6. PubMed ID: 19034051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
